Ademi LLP is investigating Jounce (NASDAQ: JNCE) for possible breaches of fiduciary duty and other violations of law in its transaction with RedX Pharma.
Ademi LLP alleges Jounce’s financial outlook and prospects are excellent and yet Jounce shareholders are expected to own approximately only Jounce shareholders approximately 37% of the share capital of the combined group. The transaction agreement unreasonably limits competing bids for Jounce by imposing a significant penalty if Jounce accepts a superior bid. Jounce insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Jounce’s board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Jounce.